An inducible kras V12 transgenic zebrafish model for liver tumorigenesis and chemical drug screening

DMM Disease Models and Mechanisms

Volumn 5, Issue 1, 2012, Pages 63-72

  Nguyen, Anh Tuan ^a   Emelyanov, Alexander ^a   Koh, Chor Hui Vivien ^a   Spitsbergen, Jan M ^b   Parinov, Serguei ^a   Gong, Zhiyuan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; LEXA PROTEIN; MIFEPRISTONE;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CELL DEATH; CONTROLLED STUDY; DRUG SCREENING; EMBRYO; GENE EXPRESSION; HYPERPLASIA; LIVER CARCINOGENESIS; LIVER TUMOR; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC ANIMAL; TRANSGENICS; TUMOR GROWTH; TUMOR REGRESSION; ZEBRA FISH;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, RAS; HUMANS; LIVER NEOPLASMS; MIFEPRISTONE; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIGNAL TRANSDUCTION; ZEBRAFISH;

DANIO RERIO;

EID: 84855892100     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.008367     Document Type: Article

References (37)

1. Amatruda, J. F. and Patton, E. E. (2008). Genetic models of cancer in zebrafish. Int. Rev. Cell Mol. Biol. 271, 1-34.
2. Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J. S., Factor, V. M. and Thorgeirsson, S. S. (2006). Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130, 1117-1128.
3. Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C. et al. (2008). Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074.
4. Diaz-Flores, E. and Shannon, K. (2007). Targeting oncogenic Ras. Genes Dev. 21, 1989-1992. (Pubitemid 47267284)
5. Downward, J. (2003). Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22.
6. Emelyanov, A. and Parinov, S. (2008). Mifepristone-inducible LexPR system to drive and control gene expression in transgenic zebrafish. Dev. Biol. 320, 113-121.
7. Emelyanov, A., Gao, Y., Naqvi, N. I. and Parinov, S. (2006). Trans-kingdom transposition of the maize dissociation element. Genetics 174, 1095-1104. (Pubitemid 44808285)
8. Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y. et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356.
9. Farazi, P. A. and DePinho, R. A. (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674-687. (Pubitemid 44286000)
10. Gomaa, A. I., Khan, S. A., Toledano, M. B., Waked, I. and Taylor-Robinson, S. D. (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 14, 4300-4308.
11. Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V. and Barbacid, M. (2003). Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120. (Pubitemid 37040827)
12. Hartmann, W., Küchler, J., Koch, A., Friedrichs, N., Waha, A., Endl, E., Czerwitzki, J., Metzger, D., Steiner, S., Wurst, P. et al. (2009). Activation of phosphatidylinositol-3′-kinase/AKT signaling is essential in hepatoblastoma survival. Clin. Cancer Res. 15, 4538-4545.
13. Her, G. M., Chiang, C. C., Chen, W. Y. and Wu, J. L. (2003). In vivo studies of liver-type fatty acid binding protein (L-FABP) gene expression in liver of transgenic zebrafish (Danio rerio). FEBS Lett. 538, 125-133. (Pubitemid 36287437)
14. Korzh, S., Pan, X., Garcia-Lecea, M., Winata, C. L., Pan, X., Wohland, T., Korzh, V. and Gong, Z. (2008). Requirement of vasculogenesis and blood circulation in late stages of liver growth in zebrafish. BMC Dev. Biol. 8, 84.
15. Lam, S. H., Wu, Y. L., Vega, V. B., Miller, L. D., Spitsbergen, J., Tong, Y., Zhan, H., Govindarajan, K. R., Lee, S., Mathavan, S. et al. (2006). Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat. Biotechnol. 24, 73-75. (Pubitemid 43083168)
16. Lambrecht, R. W., Sterling, R. K., Naishadham, D., Stoddard, A. M., Rogers, T., Morishima, C., Morgan, T. R., Bonkovsky, H. L. and HALT-C Trial Group (2011). Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 140, 1490-1500.
17. Langenau, D. M., Traver, D., Ferrando, A. A., Kutok, J. L., Aster, J. C., Kanki, J. P., Lin, S., Prochownik, E., Trede, N. S., Zon, L. I. et al. (2003). Myc-induced T cell leukemia in transgenic zebrafish. Science 299, 887-890. (Pubitemid 36182446)
18. Langenau, D. M., Keefe, M. D., Storer, N. Y., Guyon, J. R., Kutok, J. L., Le, X., Goessling, W., Neuberg, D. S., Kunkel, L. M. and Zon, L. I. (2007). Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 21, 1382-1395. (Pubitemid 46871041)
19. Liu, S. and Leach, S. D. (2011). Zebrafish models for cancer. Annu. Rev. Pathol. 6, 71-93.
20. Llovet, J. M. and Bruix, J. (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312-1327.
21. Makky, K., Tekiela, J. and Mayer, A. N. (2007). Target of rapamycin (TOR) signaling controls epithelial morphogenesis in the vertebrate intestine. Dev. Biol. 303, 501-513. (Pubitemid 46341281)
22. Newell, P., Toffanin, S., Villanueva, A., Chiang, D. Y., Minguez, B., Cabellos, L., Savic, R., Hoshida, Y., Lim, K. H., Melgar-Lesmes, P. et al. (2009). Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J. Hepatol. 51, 725-733.
23. Nguyen, A. T., Emelyanov, A., Koh, C. H. V., Spitsbergen, J. M., Lam, S. H., Mathavan, S., Parinov, S. and Gong, Z. (2011). A high level of liver-specific expression of oncogenic KrasV12 drives robust liver tumorigenesis in transgenic zebrafish. Dis. Model. Mech. 4 (Epub ahead of print).
24. Park, S. W., Davison, J. M., Rhee, J., Hruban, R. H., Maitra, A. and Leach, S. D. (2008). Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. Gastroenterology 134, 2080-2090. (Pubitemid 351783259)
25. Patton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey, R. D., Berghmans, S., Mayhall, E. A., Traver, D., Fletcher, C. D. et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249-254. (Pubitemid 40205706)
26. Roncalli, M., Park, Y. N. and DiTommaso, L. (2010). Histopathological classification of hepatocellular carcinoma. Dig. Liver Dis. 42, S228-S234.
27. Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E. and Chodosh, L. A. (2007). Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 9, 493-505. (Pubitemid 46696530)
28. Schmidt, C. M., McKillop, I. H., Cahill, P. A. and Sitzmann, J. V. (1997). Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 236, 54-58. (Pubitemid 27341838)
29. Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N. and Settleman, J. (2009). A gene expression signature associated with "K-Ras addiction"reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500.
30. Villanueva, A. and Llovet, J. M. (2011). Targeted therapies for hepatocellular carcinoma. Gastroenterology 140, 1410-1426.
31. Wee, S., Jagani, Z., Xiang, K. X., Loo, A., Dorsch, M., Yao, Y. M., Sellers, W. R., Lengauer, C. and Stegmeier, F. (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 4286-4293.
32. Weinstein, I. B. (2002). Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63-64.
33. Westerfield, M. (2000). The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio rerio), 4th edn. Eugene, OR: University of Oregon Press.
34. Yamazaki, M., Ryu, M., Okazumi, S., Kondo, F., Cho, A., Okada, T., Takayama, W., Kawashima, T., Furuki, A. and Hirata, T. (2004). Hepatoblastoma in an adult A case report and clinical review of literatures. Hepatol. Res. 30, 182-188. (Pubitemid 39654750)
35. Yoshida, R., Ogata, T., Masawa, N. and Nagai, T. (2008). Hepatoblastoma in a Noonan syndrome patient with a PTPN11 mutation. Pediatr. Blood Cancer 50, 1274-1276. (Pubitemid 351555559)
36. Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J., Fan, S. T., Luk, J. M., Wigler, M., Hannon, G. J. et al. (2006). Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253-1267. (Pubitemid 43929093)
37. Zon, L. I. and Peterson, R. T. (2005). In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4, 35-44. (Pubitemid 40109588)